Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 172

1.

Infectious corneal ulceration: a proposal for neglected tropical disease status.

Ung L, Acharya NR, Agarwal T, Alfonso EC, Bagga B, Bispo PJ, Burton MJ, Dart JK, Doan T, Fleiszig SM, Garg P, Gilmore MS, Gritz DC, Hazlett LD, Iovieno A, Jhanji V, Kempen JH, Lee CS, Lietman TM, Margolis TP, McLeod SD, Mehta JS, Miller D, Pearlman E, Prajna L, Prajna NV, Seitzman GD, Shanbhag SS, Sharma N, Sharma S, Srinivasan M, Stapleton F, Tan DT, Tandon R, Taylor HR, Tu EY, Tuli SS, Vajpayee RB, Van Gelder RN, Watson SL, Zegans ME, Chodosh J.

Bull World Health Organ. 2019 Dec 1;97(12):854-856. doi: 10.2471/BLT.19.232660. Epub 2019 Nov 1. No abstract available.

2.

MicroRNAs in Ocular Infection.

Xu S, Hazlett LD.

Microorganisms. 2019 Sep 17;7(9). pii: E359. doi: 10.3390/microorganisms7090359. Review.

3.

Glycyrrhizin Use for Multi-Drug Resistant Pseudomonas aeruginosa: In Vitro and In Vivo Studies.

Hazlett LD, Ekanayaka SA, McClellan SA, Francis R.

Invest Ophthalmol Vis Sci. 2019 Jul 1;60(8):2978-2989. doi: 10.1167/iovs.19-27200.

4.

The miR-183/96/182 Cluster Regulates Macrophage Functions in Response to Pseudomonas aeruginosa.

Muraleedharan CK, McClellan SA, Ekanayaka SA, Francis R, Zmejkoski A, Hazlett LD, Xu S.

J Innate Immun. 2019;11(4):347-358. doi: 10.1159/000495472. Epub 2019 Jan 9.

5.

HMGB1 Antagonist, Box A, Reduces TLR4, RAGE, and Inflammatory Cytokines in the Cornea of P. aeruginosa-Infected Mice.

Ekanayaka SA, McClellan SA, Peng X, Barrett RP, Francis R, Hazlett LD.

J Ocul Pharmacol Ther. 2018 Nov 8. doi: 10.1089/jop.2018.0073. [Epub ahead of print]

6.

Short Tandem Repeat (STR) Profiles of Commonly Used Human Ocular Surface Cell Lines.

McDermott AM, Baidouri H, Woodward AM, Kam WR, Liu Y, Chen X, Ziemanski JF, Vistisen K, Hazlett LD, Nichols KK, Argüeso P, Sullivan DA.

Curr Eye Res. 2018 Sep;43(9):1097-1101. doi: 10.1080/02713683.2018.1480043. Epub 2018 Jun 4.

7.

Topical Glycyrrhizin Is Therapeutic for Pseudomonas aeruginosa Keratitis.

Ekanayaka SA, McClellan SA, Barrett RP, Hazlett LD.

J Ocul Pharmacol Ther. 2018 Apr;34(3):239-249. doi: 10.1089/jop.2017.0094. Epub 2017 Dec 13.

8.

Characterization of Three Ocular Clinical Isolates of P. aeruginosa: Viability, Biofilm Formation, Adherence, Infectivity, and Effects of Glycyrrhizin.

Peng X, Ekanayaka SA, McClellan SA, Barrett RP, Vistisen K, Hazlett LD.

Pathogens. 2017 Oct 24;6(4). pii: E52. doi: 10.3390/pathogens6040052.

9.

NLRC4 regulates caspase-1 and IL-1beta production in a CD11blowLy6Glow population of cells required for resistance to Pseudomonas aeruginosa keratitis.

McClellan SA, Jerome A, Suvas S, Hazlett LD.

PLoS One. 2017 Sep 29;12(9):e0185718. doi: 10.1371/journal.pone.0185718. eCollection 2017.

10.

Glycyrrhizin Reduces HMGB1 and Bacterial Load in Pseudomonas aeruginosa Keratitis.

Ekanayaka SA, McClellan SA, Barrett RP, Kharotia S, Hazlett LD.

Invest Ophthalmol Vis Sci. 2016 Oct 1;57(13):5799-5809. doi: 10.1167/iovs.16-20103.

11.

Kruppel-like Factor 6 Promotes Macrophage-mediated Inflammation by Suppressing B Cell Leukemia/Lymphoma 6 Expression.

Kim GD, Das R, Goduni L, McClellan S, Hazlett LD, Mahabeleshwar GH.

J Biol Chem. 2016 Sep 30;291(40):21271-21282. Epub 2016 Aug 18.

12.

Inactivation of the miR-183/96/182 Cluster Decreases the Severity of Pseudomonas aeruginosa-Induced Keratitis.

Muraleedharan CK, McClellan SA, Barrett RP, Li C, Montenegro D, Carion T, Berger E, Hazlett LD, Xu S.

Invest Ophthalmol Vis Sci. 2016 Apr;57(4):1506-17. doi: 10.1167/iovs.16-19134.

13.

Thrombomodulin Protects Against Bacterial Keratitis, Is Anti-Inflammatory, but Not Angiogenic.

McClellan SA, Ekanayaka SA, Li C, Jiang X, Barrett RP, Hazlett LD.

Invest Ophthalmol Vis Sci. 2015 Dec;56(13):8091-100. doi: 10.1167/iovs.15-18393.

14.

Decreasing HMGB1 levels improves outcome of Pseudomonas aeruginosa keratitis in mice.

Hazlett LD, McClellan SA, Ekanayaka SA.

J Rare Dis Res Treat. 2016;1(1):36-39. Epub 2016 Jul 18.

15.

High-mobility group box 1: a novel target for treatment of Pseudomonas aeruginosa keratitis.

McClellan S, Jiang X, Barrett R, Hazlett LD.

J Immunol. 2015 Feb 15;194(4):1776-87. doi: 10.4049/jimmunol.1401684. Epub 2015 Jan 14.

16.

Interleukin 17 regulates Mer tyrosine kinase-positive cells in Pseudomonas aeruginosa keratitis.

Li C, McClellan SA, Barrett R, Hazlett LD.

Invest Ophthalmol Vis Sci. 2014 Oct 8;55(10):6886-900. doi: 10.1167/iovs.14-14522.

17.

IL-10 function, regulation, and in bacterial keratitis.

Hazlett LD, Jiang X, McClellan SA.

J Ocul Pharmacol Ther. 2014 Jun;30(5):373-80. doi: 10.1089/jop.2014.0018. Epub 2014 Apr 16. Review.

18.

HGF signaling impacts severity of Pseudomonas aeruginosa keratitis.

Jiang X, McClellan SA, Barrett R, Foldenauer M, Hazlett LD.

Invest Ophthalmol Vis Sci. 2014 Apr 9;55(4):2180-90. doi: 10.1167/iovs.13-13743.

19.

HIF-1α is essential for effective PMN bacterial killing, antimicrobial peptide production and apoptosis in Pseudomonas aeruginosa keratitis.

Berger EA, McClellan SA, Vistisen KS, Hazlett LD.

PLoS Pathog. 2013;9(7):e1003457. doi: 10.1371/journal.ppat.1003457. Epub 2013 Jul 18.

20.

Mammalian target of rapamycin regulates IL-10 and resistance to Pseudomonas aeruginosa corneal infection.

Foldenauer ME, McClellan SA, Berger EA, Hazlett LD.

J Immunol. 2013 Jun 1;190(11):5649-58. doi: 10.4049/jimmunol.1203094. Epub 2013 Apr 26.

21.

TREM-2 promotes host resistance against Pseudomonas aeruginosa infection by suppressing corneal inflammation via a PI3K/Akt signaling pathway.

Sun M, Zhu M, Chen K, Nie X, Deng Q, Hazlett LD, Wu Y, Li M, Wu M, Huang X.

Invest Ophthalmol Vis Sci. 2013 May 17;54(5):3451-62. doi: 10.1167/iovs.12-10938.

22.

The role of VIP in cornea.

Jiang X, McClellan SA, Barrett RP, Zhang Y, Foldenauer ME, Hazlett LD.

Invest Ophthalmol Vis Sci. 2012 Nov 7;53(12):7560-6. doi: 10.1167/iovs.12-10437.

23.

Effects of VIP on corneal reconstitution and homeostasis following Pseudomonas aeruginosa induced keratitis.

Berger EA, Vistisen KS, Barrett RP, Hazlett LD.

Invest Ophthalmol Vis Sci. 2012 Nov 1;53(12):7432-9. doi: 10.1167/iovs.12-9894.

24.

Substance P affects growth factors in Pseudomonas aeruginosa-infected mouse cornea.

Foldenauer ME, McClellan SA, Barrett RP, Zhang Y, Hazlett LD.

Cornea. 2012 Oct;31(10):1176-88. doi: 10.1097/ICO.0b013e31824d6ffd.

25.

Vasoactive intestinal peptide downregulates proinflammatory TLRs while upregulating anti-inflammatory TLRs in the infected cornea.

Jiang X, McClellan SA, Barrett RP, Zhang Y, Hazlett LD.

J Immunol. 2012 Jul 1;189(1):269-78. doi: 10.4049/jimmunol.1200365. Epub 2012 Jun 1.

26.

VIP and growth factors in the infected cornea.

Jiang X, McClellan SA, Barrett RP, Berger EA, Zhang Y, Hazlett LD.

Invest Ophthalmol Vis Sci. 2011 Aug 3;52(9):6154-61. doi: 10.1167/iovs.10-6943.

27.

Testican-1 promotes resistance against Pseudomonas aeruginosa-induced keratitis through regulation of MMP-2 expression and activation.

Berger EA, McClellan SA, Barrett RP, Hazlett LD.

Invest Ophthalmol Vis Sci. 2011 Jul 18;52(8):5339-46. doi: 10.1167/iovs.10-6920.

28.

TREM-1 amplifies corneal inflammation after Pseudomonas aeruginosa infection by modulating Toll-like receptor signaling and Th1/Th2-type immune responses.

Wu M, Peng A, Sun M, Deng Q, Hazlett LD, Yuan J, Liu X, Gao Q, Feng L, He J, Zhang P, Huang X.

Infect Immun. 2011 Jul;79(7):2709-16. doi: 10.1128/IAI.00144-11. Epub 2011 May 9.

29.

Reviews for immune privilege in the year 2010: immune privilege and infection.

Hazlett LD, Hendricks RL.

Ocul Immunol Inflamm. 2010 Aug;18(4):237-43. doi: 10.3109/09273948.2010.501946. Review.

PMID:
20662654
30.

VIP promotes resistance in the Pseudomonas aeruginosa-infected cornea by modulating adhesion molecule expression.

Berger EA, McClellan SA, Barrett RP, Hazlett LD.

Invest Ophthalmol Vis Sci. 2010 Nov;51(11):5776-82. doi: 10.1167/iovs.09-4917. Epub 2010 Jun 30.

31.

Role of the Fas pathway in Pseudomonas aeruginosa keratitis.

Zhou Z, Wu M, Barrett RP, McClellan SA, Zhang Y, Hazlett LD.

Invest Ophthalmol Vis Sci. 2010 May;51(5):2537-47. doi: 10.1167/iovs.09-4152. Epub 2009 Dec 17.

32.

Beta-defensins 2 and 3 together promote resistance to Pseudomonas aeruginosa keratitis.

Wu M, McClellan SA, Barrett RP, Zhang Y, Hazlett LD.

J Immunol. 2009 Dec 15;183(12):8054-60. doi: 10.4049/jimmunol.0902140.

33.

IL-33 shifts macrophage polarization, promoting resistance against Pseudomonas aeruginosa keratitis.

Hazlett LD, McClellan SA, Barrett RP, Huang X, Zhang Y, Wu M, van Rooijen N, Szliter E.

Invest Ophthalmol Vis Sci. 2010 Mar;51(3):1524-32. doi: 10.1167/iovs.09-3983. Epub 2009 Nov 5.

34.

Beta-defensin-2 promotes resistance against infection with P. aeruginosa.

Wu M, McClellan SA, Barrett RP, Hazlett LD.

J Immunol. 2009 Feb 1;182(3):1609-16.

35.

Rat silicone hydrogel contact lens model: effects of high- versus low-Dk lens wear.

Zhang Y, Gabriel MM, Mowrey-McKee MF, Barrett RP, McClellan S, Hazlett LD.

Eye Contact Lens. 2008 Nov;34(6):306-11. doi: 10.1097/ICL.0b013e3181891421.

36.

Substance P delays apoptosis, enhancing keratitis after Pseudomonas aeruginosa infection.

Zhou Z, Barrett RP, McClellan SA, Zhang Y, Szliter EA, van Rooijen N, Hazlett LD.

Invest Ophthalmol Vis Sci. 2008 Oct;49(10):4458-67. doi: 10.1167/iovs.08-1906. Epub 2008 Jun 19.

PMID:
18566468
37.

Substance P promotes susceptibility to Pseudomonas aeruginosa keratitis in resistant mice: anti-inflammatory mediators downregulated.

McClellan SA, Zhang Y, Barrett RP, Hazlett LD.

Invest Ophthalmol Vis Sci. 2008 Apr;49(4):1502-11. doi: 10.1167/iovs.07-1369.

PMID:
18385069
38.
39.

ST2 is essential for Th2 responsiveness and resistance to pseudomonas aeruginosa keratitis.

Huang X, Du W, Barrett RP, Hazlett LD.

Invest Ophthalmol Vis Sci. 2007 Oct;48(10):4626-33.

PMID:
17898286
40.

NKT cells are critical to initiate an inflammatory response after Pseudomonas aeruginosa ocular infection in susceptible mice.

Hazlett LD, Li Q, Liu J, McClellan S, Du W, Barrett RP.

J Immunol. 2007 Jul 15;179(2):1138-46.

41.

Bacterial infections of the cornea (Pseudomonas aeruginosa).

Hazlett LD.

Chem Immunol Allergy. 2007;92:185-194. doi: 10.1159/000099269. Review.

PMID:
17264494
42.

Spantide I decreases type I cytokines, enhances IL-10, and reduces corneal perforation in susceptible mice after Pseudomonas aeruginosa infection.

Hazlett LD, McClellan SA, Barrett RP, Liu J, Zhang Y, Lighvani S.

Invest Ophthalmol Vis Sci. 2007 Feb;48(2):797-807.

PMID:
17251480
43.

Inflammatory response to Pseudomonas aeruginosa keratitis.

Hazlett LD.

Ocul Surf. 2005 Oct;3(4 Suppl):S139-41.

PMID:
17216103
44.

Pathways of corneal and ocular surface inflammation: a perspective from the cullen symposium.

McDermott AM, Perez V, Huang AJ, Pflugfelder SC, Stern ME, Baudouin C, Beuerman RW, Burns AR, Calder VL, Calonge M, Chodosh J, Coster DJ, Dana R, Hazlett LD, Jones DB, Kim SK, Knop E, Li DQ, Mitchell BM, Niederkorn JY, Pearlman E, Wilhelmus KR, Kurie E.

Ocul Surf. 2005 Oct;3(4 Suppl):S131-8.

PMID:
17216102
46.

TLR4 is required for host resistance in Pseudomonas aeruginosa keratitis.

Huang X, Du W, McClellan SA, Barrett RP, Hazlett LD.

Invest Ophthalmol Vis Sci. 2006 Nov;47(11):4910-6.

PMID:
17065506
47.
48.

Toll-like receptors and the eye.

Yu FS, Hazlett LD.

Invest Ophthalmol Vis Sci. 2006 Apr;47(4):1255-63. Review. No abstract available.

49.

IFN-gamma: regulation of nitric oxide in the P. aeruginosa-infected cornea.

McClellan SA, Lighvani S, Hazlett LD.

Ocul Immunol Inflamm. 2006 Feb;14(1):21-8.

PMID:
16507487
50.

Pseudomonas aeruginosa-induced inflammation in the rat extended-wear contact lens model.

Szliter EA, Barrett RP, Gabriel MM, Zhang Y, Hazlett LD.

Eye Contact Lens. 2006 Jan;32(1):12-8.

PMID:
16415687

Supplemental Content

Loading ...
Support Center